We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mutations Associated with Obsessive Compulsive Disorder

By Biotechdaily staff writers
Posted on 18 Nov 2003
Researchers have found a mutation in the human serotonin transporter gene, hSERT, in unrelated families with obsessive compulsive disorder (OCD). More...
Their findings were reported in the October 23, 2003, issue of Molecular Psychiatry.

A second variant in the same gene of some patients with this mutation suggests a genetic "double hit,” which results in greater biochemical effects and more severe symptoms. Psychiatric interviews of the patients' families revealed that six of the seven individuals with the mutation had OCD and some also had anorexia nervosa, Asperger's syndrome, social phobia, tic disorder, and alcohol or other substance abuse dependence. After analyzing DNA from 170 unrelated individuals, including 80 healthy control subjects and 30 patients with OCD, eating disorders, and seasonal affective disorder, researchers detected gene variants by scanning the hSERT gene's coding sequence. They found a substitution of Val425 for lie425 in the sequence in two patients with OCD and their families but not in other patients or controls.

In addition, two original subjects and their siblings had a particular form of another hSERT variant, two long alleles of the 5-HTTLPR polymorphism. This variant suggests two changes within the same gene, both of which increase serotonin transport by themselves and may explain the unusual severity and treatment resistance of the illnesses in the subjects and their siblings.

"This is a new model for neuropsychiatric genetics, the concept of two or maybe more within-gene modifications being important in each affected individual. This is also probably the first report of a modification in a transporter gene resulting in a gain rather than a decrease in function,” noted Thomas Insel, M.D., director of the U.S. National Institute of Mental Health (Bethesda, MD, USA), which conducted the study.




Related Links:
National Institute of Mental Health

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Photo courtesy of Adobe Stock

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.